Skip to content

US · BJDX · MEDICAL - DEVICES

Bluejay Diagnostics, Inc. (BJDX) intrinsic value and stock valuation

$1.70as of 2026-11-21 · Mkt cap 1.21M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Bluejay Diagnostics, Inc. DCF and intrinsic value

InvestorsCraft values BJDX with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from BJDX’s statements →

Bluejay Diagnostics, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Medical - Devices Acton, MA 01720 bluejaydx.com

How the business is doing

Fiscal 2019–2025, USD

Revenue
$0.00
20192025
Net income
-$-6.85M
20192025
Free cash flow
-$-6.23M
20192025
Total equity
$5.98M
20192025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2019–2025, USD
20252024202320222021
Revenue$0.00$0.00$0.00$250K$0.00
Operating income-$-6.95M-$-7.17M-$-10.31M-$-9.32M-$-3.23M
Net income-$-6.85M-$-7.72M-$-9.95M-$-9.3M-$-3.73M
EPSd-$-15.22M-$-154.4M-$-331.67M-$-310M-$-124.33M
Operating cash flow-$-6.05M-$-7.82M-$-8.31M-$-7.74M-$-4.37M
Capital expenditure-$-170K-$-310K-$-700K-$-1.2M-$-20K
Free cash flow-$-6.23M-$-8.13M-$-9.02M-$-8.94M-$-4.39M
Total assets$7.12M$6.66M$4.87M$13.5M$21M
Total debt$120K$220K$350K$490K$0.00
Net debt-$-5.04M-$-4.08M-$-1.86M-$-9.62M-$-19.05M
Total equity$5.98M$5.73M$2.89M$11.5M$20.4M
Cash and short-term investments$5.16M$4.3M$2.21M$10.1M$19.1M
Income statement
20252024202320222021
Revenue$0.00$0.00$0.00$250K$0.00
Cost of revenue$0.00$0.00$0.00$200K$0.00
Gross profit$0.00$0.00$0.00$50K$0.00
Research and development expenses$3.05M$3.47M$5.71M$4.15M$1.15M
Selling, general and administrative expenses$3.91M$3.7M$4.6M$5.21M$2.08M
Other expenses$0.00$0.00$0.00$0.00$0.00
Operating expenses$6.95M$7.17M$10.3M$9.37M$3.23M
Cost and expenses$6.95M$7.17M$10.3M$9.57M$3.23M
Interest income$100K$150K$160K$90K$510K
Interest expense$0.00$820K$0.00$0.00$370K
Depreciation and amortization$170K$200K$780K$310K$150K
Ebitda-$-6.68M-$-6.7M-$-9.17M-$-8.99M-$-2.98M
Operating income-$-6.95M-$-7.17M-$-10.31M-$-9.32M-$-3.23M
Total other income/expenses, net$100K-$-550K$360K$20K-$-260K
Income before tax-$-6.85M-$-7.72M-$-9.95M-$-9.3M-$-3.49M
Income tax expense$0.00$0.00$0.00$0.00$0.00
Net income-$-6.85M-$-7.72M-$-9.95M-$-9.3M-$-3.73M
Weighted average shares outstanding$450K$50K$30K$30K$30K
Weighted average diluted shares outstanding$450K$50K$30K$30K$30K
Balance sheet
20252024202320222021
Cash and short-term investments$5.16M$4.3M$2.21M$10.1M$19.1M
Net receivables$0.00$10K$40K$0.00$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$5.46M$4.9M$3.22M$11.8M$20.7M
Property, plant and equipment, net$1.65M$1.72M$1.62M$1.7M$330K
Goodwill and intangible assets$0.00$0.00$0.00$0.00$0.00
Long-term investments$0.00$0.00$0.00$0.00$0.00
Total non-current assets$1.66M$1.76M$1.65M$1.73M$360K
Total assets$7.12M$6.66M$4.87M$13.5M$21M
Accounts payable$210K$150K$490K$640K$300K
Short-term debt$100K$110K$160K$170K$0.00
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$1.12M$810K$1.77M$1.64M$640K
Long-term debt$20K$110K$190K$320K$0.00
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$20K$120K$200K$340K-$0.00
Capital lease obligations$120K$110K$350K$490K$0.00
Total liabilities$1.14M$930K$1.97M$1.98M$640K
Common stock$0.00$0.00$0.00$0.00$0.00
Retained earnings-$-41.52M-$-34.67M-$-26.95M-$-17M-$-7.69M
Accumulated other comprehensive income (loss)$0.00$0.00$0.00$0.00$0.00
Total equity$5.98M$5.73M$2.89M$11.5M$20.4M
Total investments$0.00$0.00$0.00$0.00$0.00
Total debt$120K$220K$350K$490K$0.00
Net debt-$-5.04M-$-4.08M-$-1.86M-$-9.62M-$-19.05M
Cash flow statement
20252024202320222021
Net income-$-6.85M-$-7.72M-$-9.95M-$-9.3M-$-3.49M
Depreciation and amortization$170K$200K$780K$310K$150K
Stock-based compensation$0.00$20K$190K$430K$70K
Change in working capital$580K-$-630K$670K$580K-$-1.49M
Accounts receivable$0.00$0.00$0.00$0.00$0.00
Inventory$0.00$0.00$0.00$0.00$80K
Accounts payable$70K-$-350K-$-240K$300K-$-80K
Net cash provided by operating activities-$-6.05M-$-7.82M-$-8.31M-$-7.74M-$-4.37M
Investments in property, plant and equipment-$-170K-$-310K-$-700K-$-1.2M-$-20K
Acquisitions, net$0.00$0.00$0.00$0.00$0.00
Net cash used for investing activities-$-170K-$-310K-$-700K-$-1.2M-$-20K
Common stock issued$8.35M$12.1M$160K$10K$18.9M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00-$-20K
Net cash used for financing activities$7.09M$10.2M$1.11M$10K$22.5M
Net change in cash$860K$2.09M-$-7.91M-$-8.93M$18.1M
Cash at end of period$5.16M$4.3M$2.21M$10.1M$19.1M
Operating cash flow-$-6.05M-$-7.82M-$-8.31M-$-7.74M-$-4.37M
Capital expenditure-$-170K-$-310K-$-700K-$-1.2M-$-20K
Free cash flow-$-6.23M-$-8.13M-$-9.02M-$-8.94M-$-4.39M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Bluejay Diagnostics, Inc.

        Bluejay Diagnostics, Inc. functions as a company specializing in medical diagnostic solutions. A key offering is their Symphony platform, an advanced technological system. This platform is composed of the Symphony analyzer, which skillfully orchestrates the processing of whole blood, the isolation of biomarkers, and the preparation of immunoassays using non-contact centrifugal force. It also includes the Symphony Cartridge, which comes pre-loaded with essential reagents and components. The company additionally provides the ALLEREYE diagnostic test, a convenient, on-site device for quickly identifying allergic conjunctivitis. Bluejay Diagnostics is also progressing with the development of Symphony IL-6 tests, intended for monitoring disease advancement in critical care environments. Furthermore, they are actively creating additional diagnostic tests for their Symphony platform, such as those aimed at detecting myocardial infarction (heart attack) and congestive heart failure. Bluejay Diagnostics, Inc. was founded in 2015 and is headquartered in Acton, Massachusetts.

        CEO
        Indranil Dey
        Employees
        6
        Beta
        0.88

        Explore

        Frequently asked questions

        What is the intrinsic value of Bluejay Diagnostics, Inc. (BJDX)?

        InvestorsCraft does not currently publish an intrinsic value for BJDX. How the IC value is calculated.

        Is BJDX undervalued?

        InvestorsCraft does not publish an undervaluation signal for BJDX at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.